期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (4)
Adoptive cell therapy with T cells expressing affinity-enhanced T-cell receptors (TCRs) is a promising treatment for solid tumors. Efforts are ongoing......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (6)
Immune checkpoint blockades have been widely used to treat various malignancies. Programmed cell death protein 1 (PD-1) inhibitor-induced alopecia are......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (7)
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies, but are associated with serious adverse events like pan......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (2)
The influence of antacids use on immune checkpoint inhibitor (ICI) efficacy remains unclear. A systematic review and meta-analysis was performed to ev......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (2)
The transformation of chronic lymphocytic leukemia to an aggressive lymphoma, called Richter transformation, is often accompanied by resistance to che......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (8)
Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of cancer therapy. This study aimed to develop novel risk classifier......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (5)
Although most endometrial cancer (EC) patients have a favorable prognosis, the overall survival (OS) of metastatic and recurrent EC could hardly be im......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (8)
Checkpoint inhibition targeting programmed cell-death protein 1 has demonstrated efficacy for a wide range of indications including cutaneous malignan......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (1)
Immunotherapy has been approved for stage III non-small cell lung cancer (NSCLC) as consolidation therapy after chemoradiation in patients whose disea......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (7)
Programmed death 1 (PD-1) inhibitors have emerged as the new standard of care for the second-line treatment of advanced esophageal squamous cell carci......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (4)
Human epidermal growth factor receptor 2 (HER2) overexpression has been demonstrated in a variety of cancers. Targeted therapy with anti-HER2 monoclon......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (9)
Immune checkpoint inhibitors have improved the treatment of many cancers. However, immune-related (IR) adverse events can limit their use. A rare but ......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (8)
The emergence of immunotherapy has introduced a promising, novel approach to cancer treatment. While multiple chimeric antigen receptor (CAR) T-cell t......
期刊： JOURNAL OF IMMUNOTHERAPY, 2023; 46 (3)
Intrahepatic cholangiocarcinoma (ICC) is a common malignancy arising from the liver with limited 5-year survival. Thus, there is an urgency to explore......
